Jeanette M Tetrault1, Janet P Tate2, E Jennifer Edelman3, Adam J Gordon4, Vincent Lo Re5, Joseph K Lim3, David Rimland6, Joseph Goulet7, Stephen Crystal8, Julie R Gaither9, Cynthia L Gibert10, Maria C Rodriguez-Barradas11, Lynn E Fiellin3, Kendall Bryant12, Amy C Justice13, David A Fiellin14. 1. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT. Electronic address: jeanette.tetrault@yale.edu. 2. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; VA Connecticut Health Care System, West Haven, CT. 3. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT. 4. VA Pittsburgh Healthcare System and University of Pittsburgh, Pittsburgh, PA. 5. University of Pennsylvania School of Medicine, Philadelphia, PA. 6. VA Medical Center, Atlanta, GA; Emory University School of Medicine, Atlanta, GA. 7. VA Connecticut Health Care System, West Haven, CT; Department of Psychiatry, Yale University School of Medicine, New Haven, CT. 8. Center for Health Services Research, Institute for Health, Rutgers University. 9. Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, CT. 10. VA Medical Center Washington DC; George Washington University School of Medicine and Health Sciences, Washington, DC. 11. Michael E. DeBakey VA Medical Center and Baylor College School of Medicine, Houston, TX. 12. National Institute of Alcohol Abuse and Alcoholism, Bethesda, MD. 13. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; VA Connecticut Health Care System, West Haven, CT; Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, CT. 14. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, CT.
Abstract
INTRODUCTION: Individuals with HIV and hepatitis C (HCV) infection, alcohol use disorder, or who are prescribed potentially hepatotoxic medications may be at increased risk for buprenorphine (BUP) associated hepatotoxicity. MATERIALS AND METHODS: We examined a cohort of HIV-infected and uninfected patients receiving an initial BUP prescription between 2003 and 2012. We compared changes in alanine and aspartate aminotransferases (ALT and AST) and total bilirubin (TB) stratified by HIV status. We identified cases of liver enzyme elevation (LEE), TB elevation (TBE), and conducted chart review to assess for cases of drug induced liver injury (DILI) and death. We examined associations between age, sex, race, HIV-infection, HCV-infection, alcohol use disorder, and prescription of other potentially heptatotoxic medications with the composite endpoint of LEE, TBE, and DILI. RESULTS: Of 666 patients prescribed BUP, 36% were HIV-infected, 98% were male, 60% had RNA-confirmed HCV infection, 50% had a recent diagnosis of alcohol use disorder, and 64% were prescribed other potentially hepatotoxic medications. No clinically significant changes were observed in median ALT, AST and TB and these changes did not differ between HIV-infected and uninfected patients. Compared with uninfected patients, HIV-infected (OR 7.3, 95% CI 2.1-26.1, p=0.002), HCV-infected (OR 4.9 95% CI 1.6-15.2, p=0.007) or HIV/HCV co-infected patients (OR 6.9, 95%CI 2.1-22.2, p=0.001) were more likely to have the composite endpoint of LEE, TB elevation or DILI, in analyses that excluded 60 patients with evidence of pre-existing liver injury. 31 patients had LEE, 14/187 HIV-infected and 17/340 uninfected (p=0.25); 11 had TBE, including 9/186 HIV-infected and 2/329 uninfected (p=0.002); 8 experienced DILI, 4/202 HIV-infected and 4/204 uninfected (p=0.45). There were no significant associations with alcohol use disorder or prescription of other potentially hepatotoxic medications after adjustment for HIV/HCV status. CONCLUSIONS: Liver enzymes and TB are rarely elevated in HIV-infected and uninfected patients receiving BUP. Risk of hepatotoxicity was greater in individuals infected with HIV, HCV, or HIV/HCV co-infection, who may benefit from increased monitoring.
INTRODUCTION: Individuals with HIV and hepatitis C (HCV) infection, alcohol use disorder, or who are prescribed potentially hepatotoxic medications may be at increased risk for buprenorphine (BUP) associated hepatotoxicity. MATERIALS AND METHODS: We examined a cohort of HIV-infected and uninfected patients receiving an initial BUP prescription between 2003 and 2012. We compared changes in alanine and aspartate aminotransferases (ALT and AST) and total bilirubin (TB) stratified by HIV status. We identified cases of liver enzyme elevation (LEE), TB elevation (TBE), and conducted chart review to assess for cases of drug induced liver injury (DILI) and death. We examined associations between age, sex, race, HIV-infection, HCV-infection, alcohol use disorder, and prescription of other potentially heptatotoxic medications with the composite endpoint of LEE, TBE, and DILI. RESULTS: Of 666 patients prescribed BUP, 36% were HIV-infected, 98% were male, 60% had RNA-confirmed HCV infection, 50% had a recent diagnosis of alcohol use disorder, and 64% were prescribed other potentially hepatotoxic medications. No clinically significant changes were observed in median ALT, AST and TB and these changes did not differ between HIV-infected and uninfected patients. Compared with uninfected patients, HIV-infected (OR 7.3, 95% CI 2.1-26.1, p=0.002), HCV-infected (OR 4.9 95% CI 1.6-15.2, p=0.007) or HIV/HCV co-infectedpatients (OR 6.9, 95%CI 2.1-22.2, p=0.001) were more likely to have the composite endpoint of LEE, TB elevation or DILI, in analyses that excluded 60 patients with evidence of pre-existing liver injury. 31 patients had LEE, 14/187 HIV-infected and 17/340 uninfected (p=0.25); 11 had TBE, including 9/186 HIV-infected and 2/329 uninfected (p=0.002); 8 experienced DILI, 4/202 HIV-infected and 4/204 uninfected (p=0.45). There were no significant associations with alcohol use disorder or prescription of other potentially hepatotoxic medications after adjustment for HIV/HCV status. CONCLUSIONS: Liver enzymes and TB are rarely elevated in HIV-infected and uninfected patients receiving BUP. Risk of hepatotoxicity was greater in individuals infected with HIV, HCV, or HIV/HCV co-infection, who may benefit from increased monitoring.
Authors: Jeanette M Tetrault; Brent A Moore; Declan T Barry; Patrick G O'Connor; Richard Schottenfeld; David A Fiellin; Lynn E Fiellin Journal: J Subst Abuse Treat Date: 2012-08-29
Authors: Pamela Vergara-Rodriguez; Mary Jo Tozzi; Michael Botsko; Vijay Nandi; Frederick Altice; James E Egan; Patrick G O'Connor; Lynn E Sullivan; David A Fiellin Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Lynn E Sullivan; Declan Barry; Brent A Moore; Marek C Chawarski; Jeanette M Tetrault; Michael V Pantalon; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin Journal: Clin Infect Dis Date: 2006-12-15 Impact factor: 9.079
Authors: Shawn L Fultz; Melissa Skanderson; Larry A Mole; Neel Gandhi; Kendall Bryant; Stephen Crystal; Amy C Justice Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: M Zuin; A Giorgini; C Selmi; P M Battezzati; C A Cocchi; A Crosignani; A Benetti; P Invernizzi; M Podda Journal: Dig Liver Dis Date: 2008-02-21 Impact factor: 4.088
Authors: E Jennifer Edelman; Kirsha S Gordon; Janis Glover; Ian R McNicholl; David A Fiellin; Amy C Justice Journal: Drugs Aging Date: 2013-08 Impact factor: 3.923
Authors: Judith I Tsui; Mary A Akosile; Gwen T Lapham; Denise M Boudreau; Eric A Johnson; Jennifer F Bobb; Ingrid A Binswanger; Bobbi Jo H Yarborough; Joseph E Glass; Rebecca C Rossom; Mark T Murphy; Chinazo O Cunningham; Julia H Arnsten; Manu Thakral; Andrew J Saxon; Joseph O Merrill; Jeffrey H Samet; Gavin B Bart; Cynthia I Campbell; Amy M Loree; Angela Silva; Angela L Stotts; Brian Ahmedani; Jordan M Braciszewski; Rulin C Hechter; Thomas F Northrup; Viviana E Horigian; Katharine A Bradley Journal: J Gen Intern Med Date: 2021-02-10 Impact factor: 5.128